Related Experiment Video
Updated: Apr 22, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Wrongful termination: lessons from the Geron clinical trial
Christopher Thomas Scott1, David Magnus2
1Center for Biomedical Ethics, Stanford University, Stanford, California, USA cscott@stanford.edu.
Abstract:
Geron Corporation is a publically traded company that launched a phase I clinical trial of a human embryonic stem cell-based therapy for spinal cord injury. The company enrolled the first patient in October 2010 and stopped the trial 1 year later. The fifth patient had been enrolled but not transplanted when the company announced the trial's end. After discussions with clinical staff and family, an agreement was reached to add her to the cohort and proceed with the transplant. Two and half years later, the research is still waiting to restart. With this background in mind, we discuss the major ethical and social questions raised by the Geron case. We offer recommendations for institutional review boards and clinical sites as they deliberate approvals of early-phase trials in frontier medicine.
Insights
Geron Corporation
Area of Science:
- Stem cell therapy research
- Clinical trial ethics
- Spinal cord injury treatment
Background:
- Geron Corporation initiated a Phase I clinical trial for human embryonic stem cell therapy in spinal cord injury patients.
- The trial was halted after one year, with one patient awaiting transplantation.
Purpose of the Study:
- To discuss the ethical and social implications of the Geron Corporation's stem cell trial for spinal cord injury.
- To provide recommendations for institutional review boards and clinical sites regarding early-phase frontier medicine trials.
Main Methods:
- Case study analysis of the Geron Corporation's clinical trial.
- Discussion of ethical and social issues arising from the trial's termination and subsequent events.
Main Results:
- The Geron case highlights significant ethical and social challenges in early-phase stem cell therapy trials.
- Delays in restarting the research underscore the complexities of navigating patient consent and regulatory oversight.
Conclusions:
- The Geron case offers critical lessons for the ethical conduct of frontier medicine research.
- Recommendations are provided to guide institutional review boards and clinical sites in approving and managing novel therapeutic trials.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Nurses' Legal Responsibilities III
Cultivating a culture of collaboration and mutual respect among nurses transcends mere enhancement...
Nurses' Legal Responsibilities II
Communication between nurses and...
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
The Stanford Prison Experiment

